Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

Event Driven: Torrent Acquires JB Chemicals ~ The Second-Largest Pharma Deal in Indian History

Privi Speciality Chemicals: A Differentiated Player in Aroma Chemicals

Welspun Corp: From Pipes to Powering Global Infrastructure Growth

Shadowfax Acquires High-Value Logistics Company CriticaLog

The Beat Ideas- Groww: A Game-Changer in India’s Digital Broking Space

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Torrent Pharmaceuticals / Equity Bottom-Up

<ul>
<li>Torrent Pharmaceuticals has captured roughly 38% of India's nascent generic semaglutide market in April 2026, generating approximately INR17 crore in monthly sales within weeks of patent expiry.</li>
<li>India's anti-obesity GLP-1 market is worth INR 1,600 crore today and is forecast to reach INR 4,500-5,000 crore by 2030. Early share in a winner-takes-most therapeutic is disproportionately durable.</li>
<li>Torrent's format breadth and chronic-therapy distribution infrastructure are structural moats that one-format rivals cannot replicate quickly. </li>
</ul>


Torrent Pharmaceuticals has captured roughly 38% of India's nascent generic semaglutide market in April 2026, generating approximately INR17 crore in monthly sales within weeks of patent expiry.
India's anti-obesity GLP-1 market is worth INR 1,600 crore today and is forecast to reach INR 4,500-5,000 crore by 2030. Early share in a winner-takes-most therapeutic is disproportionately durable.
Torrent's format breadth and chronic-therapy distribution infrastructure are structural moats that one-format rivals cannot replicate quickly. 


How Torrent Won the Generic Semaglutide Race?